Trifluoroacetic acid → alpha-(R)-(3-(S)-((4-(6-ethoxy-benzo[d]isoxazol-3-yl)piperidin-1-yl)methyl)-4-(S)-phenylpyrrolidin-1-yl)-cyclohexaneacetic acid

HRID 1068148ノート

反応式

HRID 1068148 の反応式
F[C:2]1[CH:7]=[C:6](F)[CH:5]=[CH:4][C:3]=1[C:9](=[N:19][OH:20])[CH:10]1[CH2:15][CH2:14][N:13]([C:16](=O)[CH3:17])[CH2:12][CH2:11]1.[OH-].[K+].C([C@@H]1[C@@H:29]([C:30]2[CH:35]=[CH:34][CH:33]=[CH:32][CH:31]=2)[CH2:28][N:27]([C@H:36]([CH:49]2[CH2:54][CH2:53][CH2:52][CH2:51][CH2:50]2)[C:37]([O:39]CC2C=CC(OC)=CC=2)=[O:38])[CH2:26]1)=O.[C:55](O)([C:57](F)(F)F)=[O:56].C1(OC)C=CC=CC=1>CCO>[CH2:55]([O:56][C:6]1[CH:5]=[CH:4][C:3]2[C:9]([CH:10]3[CH2:15][CH2:14][N:13]([CH2:16][C@@H:17]4[C@@H:29]([C:30]5[CH:31]=[CH:32][CH:33]=[CH:34][CH:35]=5)[CH2:28][N:27]([C@H:36]([CH:49]5[CH2:54][CH2:53][CH2:52][CH2:51][CH2:50]5)[C:37]([OH:39])=[O:38])[CH2:26]4)[CH2:12][CH2:11]3)=[N:19][O:20][C:2]=2[CH:7]=1)[CH3:57]

参加物

7

反応物 5

HCID 6422Trifluoroacetic acidHCID 7519AnisoleHCID 14797Potassium HydroxideHCID 53654320alpha-(R)-(3-(R)-formyl-4-(S)-phenylpyrrolidin-1-yl)-cyclohexaneacetic acid 4-methoxybenzyl esterHCID 867570241-(4-((2,4-Difluorophenyl)-hydroxyimino-methyl)piperidin-1-yl)ethanone

生成物 1

HCID 20664145alpha-(R)-(3-(S)-((4-(6-ethoxy-benzo[d]isoxazol-3-yl)piperidin-1-yl)methyl)-4-(S)-phenylpyrrolidin-1-yl)-cyclohexaneacetic acid

試薬・触媒・溶媒 1

HCID 702Ethanol溶媒

実験手順

A solution of 1-(4-((2,4-difluorophenyl)-hydroxyimino-methyl)piperidin-1-yl)ethanone (from Step A) and KOH (45 wt. % solution) in EtOH was refluxed for 24 hours. The products were coupled with of α-(R)-(3-(R)-formyl-4-(S)-phenylpyrrolidin-1-yl)-cyclohexaneacetic acid, 4-methoxybenzyl ester (prepared above as Aldehyde 5) using a procedure analogous to that described in Example 89, Step C. The products were treated with TFA and anisole for 18 hours and concentrated under reduced pressure. The residue was purified by prep HPLC (Zorbax-RX C8 column, 30% CH3CN 15 min. and 100% CH3CN, 20 mL/min., 254 nm) to provide α-(R)-(3-(S)-((4-(6-ethoxy-benzo[d]isoxazol-3-yl)piperidin-1-yl)methyl)-4-(S)-phenylpyrrolidin-1-yl)-cyclohexaneacetic acid: ESI-MS 546 (M+1); HPLC A: 3.01 min.; and α-(R)-(3-(S)-((4-(6-fluoro-benzo[d]isoxazol-3-yl)piperidin-1-yl)methyl)-4-(S)-phenylpyrrolidin-1-yl)-cyclohexaneacetic acid: ESI-MS 520 (M+1); HPLC A: 2.88 min.

後処理

  1. concentrationconcentrated under reduced pressure
  2. customThe residue was purified by prep HPLC (Zorbax-RX C8 column, 30% CH3CN 15 min. and 100% CH3CN, 20 mL/min., 254 nm)

出典と根拠

ORDレコード
ord-b97bae13a51246a8b96f41e872f9bf65
出典データセット
uspto-grants-2001_06
特許番号
US06248755B1

反応ノート

読み込み中…